Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Authored Items
Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States
Eric M. Maiese, MHS, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Kristin A. Evans, PhD
,
Bong-Chul Chu, PhD
,
Debra E. Irwin, MSPH, PhD
February 2018 Vol 11, No 1
in
Business
,
Original Research
Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry
Mark Slomiany, PhD, MBA, MPA
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Priya Madhavan
,
Michael Kuehn
,
Sasha Richardson, MBA
July 2017 Vol 10, No 5
in
Business
Increasing Focus on Value Related to Cancer Drugs: A Payer Perspective
Matthew Mitchell, PharmD, MBA, FAMCP
July 2017, Supplement - Review of Ribociclib for Advanced Hormone Receptor–Positive Breast Cancer
in
Perspectives
The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives
Steven R. Feldman, MD, PhD
,
Gary M. Owens, MD
,
Bernard Goffe, MD
,
Gary Rice, MBA
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Mandeep Kaur, MD, MS
,
Debbie Robertson, MS, RDN, LDN
,
Debra Sierka, PharmD
,
Jeffrey A. Bourret, PharmD
,
Tamara S. Evans, PharmD, MPH, BCPS
,
Alice Gottlieb, MD, PhD
December 2016 Vol 9, No 9
in
Clinical
Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges
Alan L. Shields, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Yanni Hao, PhD
,
Meaghan Krohe, PhD
,
Andrew Yaworsky
,
Iyar Mazar, MA
,
Catherine Foley, MPH, MA
,
Faisal Mehmed, MD
,
Denise Globe, PhD
June 2016 Vol 9, No 4
in
Regulatory
Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis
Anthony M. Louder, PhD, RPh
,
Amitabh Singh, PhD
,
Kim Saverno, PhD
,
Joseph C. Cappelleri, PhD
,
Aaron J. Aten, PharmD, BCPS
,
Andrew S. Koenig, DO, FACR
,
Margaret K. Pasquale, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
April 2016 Vol 9, No 2
in
Clinical
Arming Providers and Payers with Treatment- and Value-Based Management Tools for Battling Cancer
Matthew Mitchell, PharmD, MBA, FAMCP
August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer
Lorie A. Ellis, PhD
,
Laurence Gozalo, PhD
,
Marie-Hélène Lafeuille, MA
,
Patrick Lefebvre, MA
,
Scott McKenzie, MD
,
Dominic Pilon, MA
,
Matthew Mitchell, PharmD, MBA, FAMCP
June 2015, Vol 8, No 4
in
Business
Economic Burden of Opioid-Induced Constipation Among Long-Term Opioid Users with Noncancer Pain
Shelby Corman, PharmD, MS, BCPS
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Xin Gao, PhD
,
Sizhu Liu, MS
,
Reema Mody, PhD,MBA
,
Haridarshan Patel, PharmD
,
Yin Wan, MS, BSPharm
April 2015, Vol 8, No 2
in
Business
Stakeholder Integration Needed to Address a Flawed Reimbursement System
Matthew Mitchell, PharmD, MBA, FAMCP
August 2014 Vol 7, Special Issue ASCO 2014 Payers' Perspectives in Oncology
in
Payers' Perspectives
Increasing Emphasis on Costs in the Management of Patients with Hematologic Cancers
Matthew Mitchell, PharmD, MBA, FAMCP
February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology
in
Payers' Perspectives
Modeling the Frequency and Costs Associated with Postsurgical Gastrointestinal Adverse Events for Tapentadol IR versus Oxycodone IR
Andrew Paris, MBA
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Chris M. Kozma, PhD
,
Wing Chow, PharmD, MPH
,
Anisha M. Patel, MS
,
Samir H. Mody, PharmD, MBA
,
Myoung S. Kim, PhD, MBA
November/December 2013, Vol 6, No 9
in
Business
Burden of Disease: The Psychosocial Impact of Rosacea on a Patient’s Quality of Life
Tu T. Huynh, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
July/August 2013 Vol 6, No 6
in
Clinical
Burden of Disease: The Psychosocial Impact of Rosacea on a Patient’s Quality of Life
Tu T. Huynh, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
Payer Perspectives in Dermatology
in
Clinical
,
Rosacea
Patient-Reported Outcomes Are Changing the Landscape in Oncology Care: Challenges and Opportunities for Payers
Erin A. Zagadailov, PharmD, MS
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Michael Fine, MD
,
Alan Shields, PhD
July 2013 Vol 6, No 5
in
Clinical
New Data Presented at Highlight Challenges and Opportunities for Payers
Matthew Mitchell, PharmD, MBA, FAMCP
February 2013 Vol 6, No 1, Special Issue
in
Payers' Perspectives
Diabetes Medications and Cancer Risk: Review of the Literature
Matthew Mitchell, PharmD, MBA, FAMCP
,
Lindsay Sanders, DO, MPH
,
Anu P. Michael, MD
,
Scott R. Anderson, MS IV
,
Loida D. Nguyen, PharmD, BCPS
,
Zackary A. Johnson, MS II
,
Quang T. Nguyen, DO, FACE, FTOS
July 2012, Vol 5, No 4
in
Clinical
Daily Average Consumption of 2 Long-Acting Opioids: An Interrupted Time Series Analysis
R. Amy Puenpatom, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Sheryl L. Szeinbach, PhD, RPh
,
Larry Ma, PhD
,
Rami H. Ben-Joseph, PhD
,
Kent H. Summers, PhD, BSPharm
January/February 2012, Vol 5, No 1
in
Clinical
The Economic Impact of Delaying 5-Alpha Reductase Inhibitor Therapy in Men Receiving Treatment for Symptomatic Benign Prostatic Hyperplasia
Michael Naslund, MD, MBA
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Michael Eaddy, PharmD, PhD
,
Susan L. Hogue, PharmD, MPH
,
Eric J. Kruep, PharmD, MS
,
Manan B. Shah, PharmD, PhD
May/June 2011, Vol 4, No 3
in
Business
,
Original Research
Comparing Treatment Persistence, Healthcare Resource Utilization, and Costs in Adult Patients with Major Depressive Disorder Treated with Escitalopram or Citalopram
Eric Q. Wu, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Paul E. Greenberg, MA
,
Rym Ben-Hamadi, MSc
,
Andrew P. Yu, PhD
,
Elaine H. Yang, PhD
,
M. Haim Erder, PhD
March/April 2011, Vol 4, No 2
in
Business
,
Original Research
Managing Dyslipidemia in Primary Care with Restricted Access to Lipid-Modifying Therapy
John T. Lynch, MPH
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Catherine E. Cooke, PharmD, MS (PHSR), BCPS, PAHM
,
Jonathan Rosen, MD
,
Sanjay Gandhi, PhD
,
Michael F. Bullano, PharmD
September/October 2010, Vol 3, No 5
in
Clinical
Effectiveness of Anti-Tumor Necrosis Factor Agents in the Treatment of Rheumatoid Arthritis: Observational Study
Anna D’Souza, PhD
,
Matthew Mitchell, PharmD, MBA, FAMCP
,
Brian L. Meissner, PharmD, PhD
,
Boxiong Tang, MD, PhD
,
Scott McKenzie, MD
,
Catherine T. Piech, MBA
July/August 2010, Vol 3, No 4
in
Clinical
Last modified: April 12, 2019